AU6714396A - Methods and compositions for treating cell proliferative disorders - Google Patents

Methods and compositions for treating cell proliferative disorders

Info

Publication number
AU6714396A
AU6714396A AU67143/96A AU6714396A AU6714396A AU 6714396 A AU6714396 A AU 6714396A AU 67143/96 A AU67143/96 A AU 67143/96A AU 6714396 A AU6714396 A AU 6714396A AU 6714396 A AU6714396 A AU 6714396A
Authority
AU
Australia
Prior art keywords
compositions
methods
cell proliferative
proliferative disorders
treating cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU67143/96A
Inventor
Douglas V Faller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Publication of AU6714396A publication Critical patent/AU6714396A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU67143/96A 1995-07-28 1996-07-29 Methods and compositions for treating cell proliferative disorders Abandoned AU6714396A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50900295A 1995-07-28 1995-07-28
US509002 1995-07-28
PCT/US1996/012381 WO1997004761A1 (en) 1995-07-28 1996-07-29 Methods and compositions for treating cell proliferative disorders

Publications (1)

Publication Number Publication Date
AU6714396A true AU6714396A (en) 1997-02-26

Family

ID=24024929

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67143/96A Abandoned AU6714396A (en) 1995-07-28 1996-07-29 Methods and compositions for treating cell proliferative disorders

Country Status (2)

Country Link
AU (1) AU6714396A (en)
WO (1) WO1997004761A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025365A (en) * 1997-03-25 2000-02-15 Arch Development Corp. Chelerythrine and radiation combined tumor therapy
EP1009424A2 (en) * 1997-08-29 2000-06-21 Ontogeny, Inc. Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
IL122591A0 (en) * 1997-12-14 1998-06-15 Arad Dorit Pharmaceutical compositions comprising cystein protease inhibitors
AU774861B2 (en) 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
AU2548699A (en) * 1998-02-23 1999-09-06 Rei Asakai Cell death inhibitors
US6402748B1 (en) 1998-09-23 2002-06-11 Sherwood Services Ag Electrosurgical device having a dielectrical seal
WO2001056558A1 (en) * 2000-01-31 2001-08-09 Yeda Research And Development Co. Ltd. Polycyclic dianthraquinones as anti-cancer and anti-angiogenic agents
EP1311262A4 (en) * 2000-07-28 2005-06-01 Cancer Rec Tech Ltd Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2005112912A1 (en) * 2004-04-24 2005-12-01 Sang-Hee Kim Immunomoduating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives
RU2443421C2 (en) * 2005-11-14 2012-02-27 Университэт Цюрих Staurosporin derivatives used for treating alveolar rhabdomyoblastoma
EP2014651A1 (en) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
WO2011038224A1 (en) 2009-09-24 2011-03-31 Trustees Of Boston University Methods for treating viral disorders
WO2011072086A1 (en) 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
CN103429235A (en) * 2010-12-15 2013-12-04 赖鸿政 Compounds used for treating cancer and use thereof
US9561245B2 (en) 2012-09-06 2017-02-07 The Board Of Regents Of The University Of Texas System Combination treatments for melanoma
US9572828B2 (en) 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
EP3370737B1 (en) 2015-11-04 2021-09-22 Prescient Pharma LLC Anti-aging compositions and methods for using same
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816462A (en) * 1982-05-18 1989-03-28 Nowicky Wassili Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds
JPS60178815A (en) * 1984-02-24 1985-09-12 Rikagaku Kenkyusho Carcinostatic agent
JPS62155284A (en) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd Physiologically active substance k-252 derivative

Also Published As

Publication number Publication date
WO1997004761A1 (en) 1997-02-13

Similar Documents

Publication Publication Date Title
AU4655296A (en) Compositions and methods for treating tumor cells
AU6714396A (en) Methods and compositions for treating cell proliferative disorders
IL112921A0 (en) Methods and compositions for inhibiting cell proliferative disorders
AU5439996A (en) Compositions and methods for treating pain
AU6694596A (en) Method and composition for treating asthma
AU5387796A (en) Method and compositions for treating impotence
AU3512295A (en) Composition and method for treating hair
AU2593900A (en) Composition and method for treating glaucoma
AU1296099A (en) Methods and compositions for treating dermatoses
AU7379896A (en) Method and apparatus for improving the function of sensory cells
AU1128297A (en) Composition for treating pain
AU5268696A (en) Novel compounds and methods for therapy
AU9214398A (en) Compositions and methods for treating water
AU8693098A (en) Compositions and methods for treating diabetes
AU1969997A (en) Methods and apparatus for dispensing compositions
AU4139196A (en) Method and composition for antiviral therapy
AU2113295A (en) Novel compositions and methods for water treatment
AU5979496A (en) Composition and methods for losing weight
AU2701195A (en) Methods for treating cancer and other cell proliferative diseases
AU2808997A (en) Method for treating inflammation
AU2259897A (en) Methods and compositions for the simultaneous control of rootdiseases
AU4248597A (en) Methods and compositions for treating preterm labor
AU5301296A (en) Methods and compositions for regulating fadd
AU3768795A (en) Method and compositions for hair treatment
AU5333298A (en) Compositions and methods for tumour therapy